Nisa Investment Advisors LLC Sells 275,503 Shares of Perrigo Company plc (NYSE:PRGO)

Nisa Investment Advisors LLC trimmed its holdings in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 90.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,445 shares of the company's stock after selling 275,503 shares during the period. Nisa Investment Advisors LLC's holdings in Perrigo were worth $826,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of PRGO. State of Alaska Department of Revenue grew its holdings in Perrigo by 2.8% during the first quarter. State of Alaska Department of Revenue now owns 15,984 shares of the company's stock worth $448,000 after acquiring an additional 430 shares during the period. Cedar Wealth Management LLC grew its holdings in Perrigo by 2.1% during the fourth quarter. Cedar Wealth Management LLC now owns 21,966 shares of the company's stock worth $565,000 after acquiring an additional 450 shares during the period. Fox Run Management L.L.C. grew its holdings in Perrigo by 5.1% during the fourth quarter. Fox Run Management L.L.C. now owns 11,381 shares of the company's stock worth $293,000 after acquiring an additional 548 shares during the period. Linden Thomas Advisory Services LLC grew its holdings in Perrigo by 3.8% during the first quarter. Linden Thomas Advisory Services LLC now owns 19,707 shares of the company's stock worth $553,000 after acquiring an additional 724 shares during the period. Finally, Snowden Capital Advisors LLC grew its holdings in Perrigo by 3.6% during the fourth quarter. Snowden Capital Advisors LLC now owns 24,337 shares of the company's stock worth $626,000 after acquiring an additional 842 shares during the period. 95.91% of the stock is owned by institutional investors and hedge funds.

Perrigo Stock Up 0.1%

Shares of PRGO traded up $0.02 during midday trading on Thursday, reaching $27.11. 298,541 shares of the stock were exchanged, compared to its average volume of 1,430,410. The firm has a 50 day simple moving average of $26.81 and a 200-day simple moving average of $26.10. The company has a quick ratio of 1.28, a current ratio of 2.36 and a debt-to-equity ratio of 0.82. Perrigo Company plc has a 12-month low of $23.14 and a 12-month high of $30.93. The company has a market cap of $3.73 billion, a price-to-earnings ratio of -20.62 and a beta of 0.45.

Perrigo (NYSE:PRGO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.56 by $0.04. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a positive return on equity of 8.93% and a negative net margin of 4.16%. The firm's revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.29 EPS. Research analysts forecast that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 17th. Stockholders of record on Friday, May 30th were paid a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 4.28%. The ex-dividend date was Friday, May 30th. Perrigo's dividend payout ratio (DPR) is presently -88.55%.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Perrigo from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $33.00.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.